Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Receives $14.83 Average Target Price from Analysts

Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) have been assigned a consensus recommendation of “Moderate Buy” from the six brokerages that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $14.8333.

Several analysts have weighed in on KPTI shares. Wall Street Zen raised Karyopharm Therapeutics from a “strong sell” rating to a “hold” rating in a report on Saturday, November 8th. The Goldman Sachs Group set a $12.00 price target on shares of Karyopharm Therapeutics in a research note on Wednesday, December 17th. Robert W. Baird cut their price objective on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday, October 9th. Piper Sandler reaffirmed an “overweight” rating and set a $12.00 target price on shares of Karyopharm Therapeutics in a report on Wednesday, December 17th. Finally, HC Wainwright upgraded shares of Karyopharm Therapeutics from a “neutral” rating to a “buy” rating and set a $15.00 target price for the company in a research report on Monday, October 13th.

Karyopharm Therapeutics Stock Performance

NASDAQ:KPTI opened at $5.95 on Friday. The company has a market cap of $108.94 million, a price-to-earnings ratio of -0.41 and a beta of 0.21. The stock’s fifty day moving average price is $6.58 and its two-hundred day moving average price is $5.95. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $10.80.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its earnings results on Monday, November 3rd. The company reported ($3.82) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.30) by ($0.52). The firm had revenue of $44.04 million during the quarter, compared to the consensus estimate of $39.56 million. On average, equities analysts predict that Karyopharm Therapeutics will post -0.71 EPS for the current fiscal year.

Hedge Funds Weigh In On Karyopharm Therapeutics

Hedge funds have recently added to or reduced their stakes in the stock. Bank of America Corp DE grew its position in shares of Karyopharm Therapeutics by 26.8% during the 2nd quarter. Bank of America Corp DE now owns 168,534 shares of the company’s stock worth $726,000 after buying an additional 35,626 shares during the period. ADAR1 Capital Management LLC bought a new position in Karyopharm Therapeutics during the 3rd quarter worth approximately $164,000. Bridgeway Capital Management LLC acquired a new position in Karyopharm Therapeutics during the second quarter valued at approximately $163,000. XTX Topco Ltd acquired a new position in Karyopharm Therapeutics during the second quarter valued at approximately $56,000. Finally, Baird Financial Group Inc. bought a new stake in Karyopharm Therapeutics in the second quarter valued at approximately $45,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.